InterCure Responds to Israeli Security Crisis: Operations Impact and Company Commitment Highlighted

TEL AVIV — InterCure Ltd., operating as Canndoc, a medical cannabis firm in Israel and globally outside North America, today addressed the recent security situation in Israel and its repercussions on the company’s operations and employees.

On October 7, 2023, Israel’s southern border witnessed a breach by Hamas terrorists who launched a series of attacks on both civilian and military targets. In addition to the ground invasion, there were extensive rocket assaults on various regions within Israel. The Israeli security cabinet declared war against Hamas following these incidents.

InterCure’s primary facility, situated approximately 2 km from the Gaza border in Kibbutz Nir Oz, is in close proximity to these conflict zones. As a result, the facility has been marked as a closed military zone by the Israeli authorities since the conflict began. The company is currently unable to determine the exact extent of damage to the site or the necessary rehabilitation steps.

However, despite these adversities, InterCure’s management, trading, and pharmacy units are diligently working to cater to patient needs and the surging demand for its products. While the facility in Nir Oz remains compromised, the company’s other operations, both within Israel and internationally, are functioning efficiently and have been directed to increase production levels.

Given the war’s unpredictable duration and its potential long-term ramifications, InterCure has yet to assess the full impact on its financial standing. Nonetheless, the company is optimistic about receiving compensation from the Israeli government for damages.

During these trying times, InterCure is committed to providing support to affected communities in the Israeli Southern Border region. The company has decided to distribute its products, free of charge, to assist with various medical needs, including pain management and trauma care.

Alexander Rabinovich, CEO of InterCure, expressed his gratitude to the Israeli Defense Forces for their valor and dedication. He also lauded InterCure’s employees for their unwavering commitment and swift mobilization during the conflict. Rabinovich reaffirmed the company’s mission to bring relief and voiced his optimism by stating, “Together, we will win. עם ישראל חי.”

About InterCure (dba Canndoc): InterCure, trading as Canndoc, stands as a preeminent cannabis company outside North America. Canndoc, a fully-owned subsidiary of InterCure, has established itself as Israel’s top licensed cannabis producer. It boasts Good Manufacturing Practices (GMP) certification and offers pharmaceutical-grade medical cannabis products. Leveraging its robust distribution network and a high-margin “seed-to-sale” model, InterCure seeks to dominate the rapidly expanding global cannabis market outside of North America.